Residency · Residency · Neurology

Neuromyelitis Optica Spectrum Disorder

Introduction

Neuromyelitis optica spectrum disorder (NMOSD) is a severe autoimmune astrocytopathy predominantly targeting the optic nerves and spinal cord. The discovery of the aquaporin-4 (AQP4) antibody transformed NMOSD from a variant of MS into a distinct disease entity with unique pathogenesis, treatment, and prognosis. Early recognition is critical because MS therapies can worsen NMOSD.

Epidemiology

NMOSD has a prevalence of approximately 1-5 per 100,000 and is more common in non-White populations. There is a striking female predominance with a 9:1 female-to-male ratio in AQP4-seropositive disease. The median age of onset is 35-45 years, though it can occur in children and the elderly. NMOSD is associated with other autoimmune conditions including SLE, Sjogren syndrome, myasthenia gravis, and thyroid disease.

Pathophysiology

AQP4-IgG binds aquaporin-4 water channels on astrocyte foot processes at the blood-brain barrier. Complement-dependent cytotoxicity leads to astrocyte destruction, with secondary oligodendrocyte injury and demyelination. There is predilection for AQP4-rich regions including the optic chiasm, area postrema, and periependymal spinal cord. MOG-IgG defines a separate entity (MOG antibody-associated disease) with overlapping but distinct features.

Clinical Features

Core Clinical Syndromes

Optic neuritis in NMOSD is often bilateral and severe with poor recovery, and may involve the chiasm. Longitudinally extensive transverse myelitis (LETM) spans 3 or more vertebral segments with often central cord involvement. Area postrema syndrome manifests as intractable nausea, vomiting, and hiccups lasting days to weeks. Acute brainstem syndrome produces periependymal lesions causing diplopia, facial palsy, or trigeminal neuralgia. Diencephalic syndrome causes narcolepsy-like hypersomnia and hypothalamic dysfunction. Cerebral syndrome with large, confluent, or tumefactive white matter lesions is rare.

Diagnosis

2015 International Consensus Diagnostic Criteria

For AQP4-IgG seropositive patients, the diagnosis requires at least one core clinical characteristic plus positive AQP4-IgG (cell-based assay preferred). For AQP4-IgG seronegative or unknown status, at least two core characteristics are required with additional MRI requirements and exclusion of alternative diagnoses.

Key Investigations

AQP4-IgG should be tested by cell-based assay (sensitivity approximately 76%, specificity above 99%). If AQP4-IgG is negative, MOG-IgG should be tested by cell-based assay. MRI of the brain and complete spine with gadolinium is essential. CSF typically shows pleocytosis (often above 50 cells, which may include neutrophils) and elevated protein; oligoclonal bands are typically absent, unlike MS. Optical coherence tomography (OCT) demonstrates severe retinal nerve fiber layer thinning.

Distinguishing NMOSD from MS

LETM spanning 3 or more segments favors NMOSD, while MS lesions typically span fewer than 2 segments. Bilateral or chiasmal optic neuritis favors NMOSD. Absence of CSF oligoclonal bands favors NMOSD. Brain MRI may be normal or show lesions in AQP4-rich periependymal regions rather than the typical periventricular pattern of MS.

Acute Attack Treatment

First-line treatment is IV methylprednisolone 1 g daily for 5 days. Plasma exchange (PLEX) should be initiated early if the attack is steroid-refractory or severe, with 5-7 exchanges performed. Early PLEX is associated with better functional outcomes, particularly in transverse myelitis. Critically, interferon-beta, natalizumab, and fingolimod must not be used because these MS therapies can exacerbate NMOSD.

Long-Term Immunotherapy

FDA-Approved Therapies (AQP4-IgG Seropositive)

Eculizumab is a terminal complement inhibitor (anti-C5) that demonstrated a 94% reduction in relapse risk in the PREVENT trial. Inebilizumab is an anti-CD19 B-cell depleting antibody that showed a 73% reduction in attacks in the N-MOmentum trial. Satralizumab is an anti-IL-6 receptor antibody that demonstrated significant relapse reduction in the SAkuraStar and SAkuraSky trials.

Off-Label Therapies

Rituximab (anti-CD20 B-cell depletion) is widely used with strong observational evidence. Azathioprine is a conventional immunosuppressant that is less effective but accessible. Mycophenolate mofetil is an alternative oral immunosuppressant. Treatment is typically lifelong given the high relapse severity and cumulative disability that characterize NMOSD.

Clinical Pearls

NMOSD attacks are often severe with incomplete recovery, making aggressive early treatment of relapses essential. AQP4-IgG should always be tested using a cell-based assay before initiating MS-specific therapies in patients presenting with optic neuritis or transverse myelitis. Area postrema syndrome (intractable vomiting and hiccups) is a highly specific NMOSD presentation that is often misdiagnosed as a gastrointestinal disorder. MS disease-modifying therapies (interferons, fingolimod, natalizumab) can worsen NMOSD and must be avoided.

References

• Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177-189.
• Pittock SJ, Berthele A, Fujihara K, et al. Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381(7):614-625.
• Cree BAC, Bennett JL, Kim HJ, et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised, placebo-controlled phase 2/3 trial. Lancet. 2019;394(10206):1352-1363.
• Yamamura T, Kleiter I, Fujihara K, et al. Trial of satralizumab in neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381(22):2114-2124.

Read this lecture as Markdown